维奈克拉联合阿扎胞苷治疗复发难治性急性髓系白血病4例

Four cases of relapsed and refractory acute myeloid leukemia treated with venetoclax combined with azacitidine

复发难治性急性髓系白血病对普通化疗药物反应不敏感、疗效较差,而BCL-2抑制剂维奈克拉可促进白血病细胞凋亡并克服耐药性,并在临床上得到了一定的验证。本文研究了4例复发难治性急性髓系白血病患者,临床应用BCL-2抑制剂维奈克拉联合去甲基化药物阿扎胞苷进行治疗。统计化疗期间患者的各项指标,观察治疗效果,发现4例患者治疗后均达完全缓解,血液学不良反应主要表现为中性粒细胞减少,非血液学不良反应主要表现为胃肠道反应,给予对症处理后患者均可耐受。因此本研究结果显示,维奈克拉联合阿扎胞苷是治疗复发难治性急性髓系白血病的一种新选择。

Relapsed and refractory acute myeloid leukemia is insensitive and less effective in response to common chemotherapeutic drugs,while the BCL-2 inhibitor-venetoclax can promote apoptosis of leukemic cells and overcome drug resistance,which has been clinically validated.This paper herein demonstrates a study on four patients with relapsed and refractory acute myeloid leukemia who were clinically treated with BCL-2 inhibitor-venetoclax combined with demethylating drug-azacitidine.The patients’indexes during chemotherapy were recorded and the efficacy was observed.And it was found that all four patients were completely remitted after treatment,with hematological adverse reactions being mainly neutropenia and non-hematological adverse reactions mainly gastrointestinal reactions,which were tolerated by the patients after symptomatic treatment.Therefore,the results of this study suggest that venetoclax combined with azacitidine can be a new treatment option for relapsed and refractory acute myeloid leukemia.